Literature DB >> 9832411

Biological response to ErbB ligands in nontransformed cell lines correlates with a specific pattern of receptor expression.

S Sundaresan1, P E Roberts, K L King, M X Sliwkowski, J P Mather.   

Abstract

The human epidermal growth factor receptor (HER or ErbB) family consists of four distinct members, including the epidermal growth factor (EGF) receptor (EGFR, HER1, or ErbB1), ErbB2 (HER2 or neu), ErbB3 (HER3), and ErbB4 (HER4). Activation of these receptors plays an important role in the regulation of cell proliferation, differentiation, and survival in several different tissues. Binding of a specific ligand to one of the ErbB receptors triggers the formation of specific receptor homo- and heterodimers, with ErbB2 being the preferred signaling partner. We analyzed the levels of various ErbB receptor messenger RNAs in a series of nontransformed cell lines by real time quantitative RT-PCR. The cell lines chosen were derived from a variety of tissues, including pancreas, lung, heart, and nervous system. Further, we measured biological responses in these cell lines upon treatment with EGF, betacellulin, and two types of neuregulins, heregulin and sensory and motor neuron-derived factor. All cell lines examined expressed detectable levels of ErbB2. High levels of expression of ErbB3 were correlated with responsiveness to heregulin and sensory and motor neuron-derived factor, whereas high levels of EGFR expression were correlated with responsiveness to EGF and betacellulin. Moreover, the sensitivity of a cell line to ErbB ligands was also correlated with the levels of expression of the appropriate ErbB receptors in that cell line. These results are consistent with our hypothesis that appropriate biological responsiveness to ErbB ligands is determined by the levels of expression of specific ErbB receptor combinations within a given tissue.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9832411     DOI: 10.1210/endo.139.12.6378

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  14 in total

Review 1.  Neuregulin signaling via erbB receptor assemblies in the nervous system.

Authors:  Sean Murphy; Randy Krainock; Muly Tham
Journal:  Mol Neurobiol       Date:  2002-02       Impact factor: 5.590

Review 2.  Roles of transforming growth factor-alpha and related molecules in the nervous system.

Authors:  C J Xian; X F Zhou
Journal:  Mol Neurobiol       Date:  1999 Oct-Dec       Impact factor: 5.590

3.  Identification of betacellulin as a major peptide growth factor in milk: purification, characterization and molecular cloning of bovine betacellulin.

Authors:  A J Dunbar; I K Priebe; D A Belford; C Goddard
Journal:  Biochem J       Date:  1999-12-15       Impact factor: 3.857

4.  Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased.

Authors:  Rachel M Gonzalez; Don S Daly; Ruimin Tan; Jeffrey R Marks; Richard C Zangar
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-05-17       Impact factor: 4.254

5.  Presence of EGF growth factor ligands and their effects on cultured rat conjunctival goblet cell proliferation.

Authors:  Jian Gu; Lili Chen; Marie A Shatos; J David Rios; Abha Gulati; Robin R Hodges; Darlene A Dartt
Journal:  Exp Eye Res       Date:  2007-11-17       Impact factor: 3.467

Review 6.  The ERBB3 receptor in cancer and cancer gene therapy.

Authors:  G Sithanandam; L M Anderson
Journal:  Cancer Gene Ther       Date:  2008-04-11       Impact factor: 5.987

7.  Effects of silymarin on the spontaneous proliferation and cell cycle of human peripheral blood leukemia T cells.

Authors:  Marjan Gharagozloo; Zahra Amirghofran
Journal:  J Cancer Res Clin Oncol       Date:  2007-04-14       Impact factor: 4.322

8.  Betacellulin-induced beta cell proliferation and regeneration is mediated by activation of ErbB-1 and ErbB-2 receptors.

Authors:  Yoon Sin Oh; Seungjin Shin; Youn-Jung Lee; Eung Hwi Kim; Hee-Sook Jun
Journal:  PLoS One       Date:  2011-08-29       Impact factor: 3.240

9.  Anti-erbB2 treatment induces cardiotoxicity by interfering with cell survival pathways.

Authors:  Thea Pugatsch; Suzan Abedat; Chaim Lotan; Ronen Beeri
Journal:  Breast Cancer Res       Date:  2006       Impact factor: 6.466

10.  Promotion of breast cancer by beta-hexachlorocyclohexane in MCF10AT1 cells and MMTV-neu mice.

Authors:  Patrick S Wong; Fumio Matsumura
Journal:  BMC Cancer       Date:  2007-07-17       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.